Navigation Links
Eurand to Present Zentase Phase III Data

MILAN, Italy, and DAYTON, Ohio, June 08, 2007 /PRNewswire-FirstCall/ --Eurand to present data on Zentase at European Cystic Fibrosis Society Annual Meeting. .

-- Exocrine pancreatic insufficiency (EPI) is a deficiency of digestive

enzymes normally produced by the pancreas that can result from a number

of diseases, including cystic fibrosis, chronic pancreatitis, and

pancreatic cancer


-- EPI results in poor digestion and reduced absorption of nutrients

which, if untreated, can lead to impaired growth in children, impaired

immune response and shortened life expectancy


-- Treatment with pancreatic replacement products replaces enzymes lost

through this disease. Other than enzyme replacement, no known

alternative therapy for the loss of digestive enzymes is currently

available


-- Eurand completed two phase III clinical trials on its lead product

candidate, Zentase(TM), for the treatment of EPI


-- Eurand expects to initiate a rolling submission of its new drug

application (NDA) with the US Food and Drug Administration (FDA) for

Zentase for the treatment of EPI in the 2nd quarter of this year


-- Posters 243-246 will be presented on June 15th between 1:30-2:30pm:


1. Zentase, a New Pancreatic Enzyme Product (PEP), Is Safe and

Effective in Cystic Fibrosis (CF) Patients with Exocrine Pancreatic

Insufficiency (EPI)

2. Zentase, a New Pancreatic Enzyme Product (PEP), in Young Cystic

Fibrosis (CF) Patients with Exocrine Pancreatic Insufficiency (EPI)
< br /> 3. Child friendly dosing options for PEPs

4. Overfilling in Current Pancreatic Enzyme Products (PEPs): Still an

Unresolved Issue


For more information on Zentase and Eurand

Contact: Marian Cutler, Eurand, +1-973-517-0519

This media alert, and oral statements made with respect to information contained in this release, constitutes forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to Eurand's plans for our NDA filing, enrollment and future plans for our clinical trials, progress of and reports of results from clinical studies, clinical development plans and product development activities. The words "expect" and similar expressions also identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with the possibility that the FDA refuses to approve our NDA; the outcome of any discussions with the FDA; and unexpected delays in preparation of materials for submission to the FDA as apart of our NDA filing. Forward looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward- looking statements.

CONTACT: Marian Cutler of Eurand, +1-973-517-0519

Web site: http://www.eurand.com/

Ticker Symbol: (:EURX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
2. Eurand Announces Positive Phase III Clinical Study Results
3. The Past, Present and Future of HLA Typing
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... YORK , Feb. 23, 2017  The ... 330.6 million by 2021 from USD 275.9 million ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... increasing spending on pharmaceutical R&D, and growth in ... driving the market growth for particle counters. On ...
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Disorder Drugs Price Analysis and Strategies - 2016" report to ... ... - 2016, provides drug pricing data and benchmarks in the global ... What are the key drugs marketed ...
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... The narrative in “ Signal 8: An Australian Paramedic’s ... of his paramedic experiences. Schanssema describes the tragedies he saw, as well as his ... them. , Schanssema, initially unsure of the career path he wanted to take, found ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating ... Me Beyond What You See” body image mannequin art competition. Selected from 15 submissions ... and the winner revealed at the 31st annual iaedp Symposium, March 22 – 26 ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... Senior International Elite division on February 12th. Ms. Esparza qualified into this ... elite qualifier competition held in Las Vegas, Nevada. Frida is one of approximately ...
(Date:2/23/2017)... ... , ... The 89th Academy Awards will be celebrated this weekend, which means ... Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” to the ... Center for American Progress (CAP), for its report, Lessons From State Performance on NAEP: ...
(Date:2/23/2017)... ... ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will be appearing ... which will begin airing on February 24, 2017. The show chronicles the weight loss ... television series, “Here Comes Honey Boo Boo.” The earlier series from TLC lasted for ...
Breaking Medicine News(10 mins):